Standout Papers

Breast Cancer Treatment 2005 2026 2012 2019 3.1k
  1. Breast Cancer Treatment (2019)
    Adrienne G. Waks, Eric P. Winer JAMA
  2. Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer (2018)
    Peter Schmid, Sylvia Adams et al. New England Journal of Medicine
  3. American Society of Clinical Oncology Guideline Recommendations for Sentinel Lymph Node Biopsy in Early-Stage Breast Cancer (2005)
    Gary H. Lyman, Armando E. Giuliano et al. Journal of Clinical Oncology
  4. CDK4/6 inhibition triggers anti-tumour immunity (2017)
    Shom Goel, Molly J. DeCristo et al. Nature
  5. Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial (2019)
    Peter Schmid, Hope S. Rugo et al. The Lancet Oncology
  6. Lumpectomy Plus Tamoxifen With or Without Irradiation in Women Age 70 Years or Older With Early Breast Cancer: Long-Term Follow-Up of CALGB 9343 (2013)
    Kevin S. Hughes, Lauren A. Schnaper et al. Journal of Clinical Oncology
  7. Lumpectomy plus Tamoxifen with or without Irradiation in Women 70 Years of Age or Older with Early Breast Cancer (2004)
    Kevin S. Hughes, Lauren A. Schnaper et al. New England Journal of Medicine
  8. Hydrocortisone With or Without Mitoxantrone in Men With Hormone-Refractory Prostate Cancer: Results of the Cancer and Leukemia Group B 9182 Study (1999)
    Philip W. Kantoff, Susan Halabi et al. Journal of Clinical Oncology
  9. Trastuzumab Plus Adjuvant Chemotherapy for Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Planned Joint Analysis of Overall Survival From NSABP B-31 and NCCTG N9831 (2014)
    Edith A. Perez, Edward H. Romond et al. Journal of Clinical Oncology
  10. Triple-negative breast cancer: disease entity or title of convenience? (2010)
    Lisa A. Carey, Eric P. Winer et al. Nature Reviews Clinical Oncology
  11. Impact of the Addition of Carboplatin and/or Bevacizumab to Neoadjuvant Once-per-Week Paclitaxel Followed by Dose-Dense Doxorubicin and Cyclophosphamide on Pathologic Complete Response Rates in Stage II to III Triple-Negative Breast Cancer: CALGB 40603 (Alliance) (2014)
    William M. Sikov, Donald A. Berry et al. Journal of Clinical Oncology
  12. American Society of Clinical Oncology Clinical Practice Guideline: Update on Adjuvant Endocrine Therapy for Women With Hormone Receptor–Positive Breast Cancer (2010)
    Harold J. Burstein, Ann Alexis Prestrud et al. Journal of Clinical Oncology
  13. Web-Based Survey of Fertility Issues in Young Women With Breast Cancer (2004)
    Ann H. Partridge, Shari Gelber et al. Journal of Clinical Oncology
  14. Adjuvant Endocrine Therapy for Women With Hormone Receptor–Positive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Focused Update (2014)
    Harold J. Burstein, Sarah Temin et al. Journal of Clinical Oncology
  15. Nonadherence to Adjuvant Tamoxifen Therapy in Women With Primary Breast Cancer (2003)
    Ann H. Partridge, Philip S. Wang et al. Journal of Clinical Oncology
  16. Central nervous system metastases in women who receive trastuzumab‐based therapy for metastatic breast carcinoma (2003)
    Johanna C. Bendell, Susan M. Domchek et al. Cancer
  17. CNS Metastases in Breast Cancer (2004)
    Nancy U. Lin, Jennifer R. Bellon et al. Journal of Clinical Oncology
  18. Sites of distant recurrence and clinical outcomes in patients with metastatic triple‐negative breast cancer (2008)
    Nancy U. Lin, Elizabeth B. Claus et al. Cancer
  19. Estrogen-Receptor Status and Outcomes of Modern Chemotherapy for Patients With Node-Positive Breast Cancer (2006)
    Donald A. Berry, Constance Cirrincione et al. JAMA
  20. Circulating Tumor Cells and Response to Chemotherapy in Metastatic Breast Cancer: SWOG S0500 (2014)
    Jeffrey B. Smerage, William E. Barlow et al. Journal of Clinical Oncology
  21. Clinicopathologic features, patterns of recurrence, and survival among women with triple‐negative breast cancer in the National Comprehensive Cancer Network (2012)
    Nancy U. Lin, Ann Vanderplas et al. Cancer
  22. Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study (2018)
    Sylvia Adams, Sherene Loi et al. Annals of Oncology
  23. Adjuvant Paclitaxel and Trastuzumab for Node-Negative, HER2-Positive Breast Cancer (2015)
    Sara M. Tolaney, William T. Barry et al. New England Journal of Medicine
  24. Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study (2014)
    Joyce F. Liu, William T. Barry et al. The Lancet Oncology
  25. Estimating the benefits of therapy for early-stage breast cancer: the St. Gallen International Consensus Guidelines for the primary therapy of early breast cancer 2019 (2019)
    Harold J. Burstein, Giuseppe Curigliano et al. Annals of Oncology
  26. Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years (2016)
    Paul E. Goss, James N. Ingle et al. New England Journal of Medicine
  27. Adjuvant Endocrine Therapy for Women With Hormone Receptor–Positive Breast Cancer: ASCO Clinical Practice Guideline Focused Update (2018)
    Harold J. Burstein, Christina Lacchetti et al. Journal of Clinical Oncology
  28. Enzalutamide for the Treatment of Androgen Receptor–Expressing Triple-Negative Breast Cancer (2018)
    Tiffany A. Traina, Kathy D. Miller et al. Journal of Clinical Oncology
  29. Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial (2021)
    Eric P. Winer, Seock‐Ah Im et al. The Lancet Oncology
  30. First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis (2021)
    Leisha A. Emens, Sylvia Adams et al. Annals of Oncology
  31. Atezolizumab and nab-Paclitaxel in Advanced Triple-Negative Breast Cancer: Biomarker Evaluation of the IMpassion130 Study (2021)
    Leisha A. Emens, Luciana Molinero et al. JNCI Journal of the National Cancer Institute
  32. STING agonism reprograms tumor-associated macrophages and overcomes resistance to PARP inhibition in BRCA1-deficient models of breast cancer (2022)
    Qiwei Wang, Johann S. Bergholz et al. Nature Communications

Immediate Impact

1 by Nobel laureates 11 from Science/Nature 113 standout
Sub-graph 1 of 21

Citing Papers

Probiotic-guided CAR-T cells for solid tumor targeting
2023 StandoutScience
Deciphering breast cancer: from biology to the clinic
2023 Standout
26 intermediate papers

Works of Eric P. Winer being referenced

LBA17 Overall survival (OS) results from the phase III MONALEESA-2 (ML-2) trial of postmenopausal patients (pts) with hormone receptor positive/human epidermal growth factor receptor 2 negative (HR+/HER2−) advanced breast cancer (ABC) treated with endocrine therapy (ET) ± ribociclib (RIB)
2021
Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer
2018 Standout
and 46 more

Author Peers

Author Last Decade Papers Cites
Eric P. Winer 35888 19716 13979 730 55.0k
Larry Norton 29114 15708 7885 528 49.6k
Daniel F. Hayes 25941 20441 9264 407 45.3k
Martine Piccart 26838 16098 9035 830 41.8k
Clifford A. Hudis 23054 13808 6733 509 38.8k
Giuseppe Viale 28609 25471 9264 766 53.8k
Mitch Dowsett 31319 24499 12269 779 57.9k
Gabriel N. Hortobágyi 53018 36270 16220 1.1k 86.1k
Hope S. Rugo 30324 11168 15990 833 43.5k
Gary M. Clark 27959 14287 10472 265 43.7k
Ian O. Ellis 27787 26157 6928 971 58.9k

All Works

Loading papers...

Rankless by CCL
2026